|
Females
|
373 (45.6)
|
|
Males
|
445 (54.4)
|
|
Age, years
|
|
Range
|
15.2–95.6
|
|
Median (interquartile range)
|
69.4 (59.3–76.8)
|
|
Charlson comorbidity index
|
|
0
|
434 (53.1)
|
|
1–2
|
270 (33.0)
|
|
> 2
|
114 (13.9)
|
|
No. bacteraemic episodes
|
|
0
|
410 (50.1)
|
|
1
|
215 (26.3)
|
|
2
|
93 (11.4)
|
|
3
|
61 (7.5)
|
|
4
|
20 (2.4)
|
|
5–9
|
19 (2.3)
|
|
Microbiological isolates, first bacteraemic episode
|
|
Mono-microbial Gram-positive
|
349 (42.7)
|
|
Staphylococcus aureus
|
27 (3.5)
|
|
Coagulase-negative staphylococci
|
112 (14.3)
|
|
Streptococcus pneumoniae
|
12 (1.5)
|
|
Streptococci, other
|
10 (1.3)
|
|
Enterococcus faecalis
|
134 (17.1)
|
|
Other
|
54 (6.9)
|
|
Mono-microbial Gram-negative
|
308 (37.7)
|
|
Escherichia coli
|
127 (16.2)
|
|
Klebsiella spp.
|
53 (6.8)
|
|
Pseudomonas aeruginosa
|
30 (3.8)
|
|
Other
|
98 (12.5)
|
|
Mono-microbial fungi
|
18 (2.3)
|
|
Poly-microbial
|
107 (13.7)
|
|
Neutrophil granulocytes (10^9/L)
|
|
< 0.5
|
182 (22.2)
|
|
0.5–0.9
|
78 (9.5)
|
|
1.0–1.4
|
44 (5.4)
|
|
≥ 1.5
|
215 (26.3)
|
|
Not measured
|
299 (36.6)
|
|
Bone marrow biopsy blast percentage
|
|
0–19
|
14 (1.7)c
|
|
20–39
|
283 (34.6)
|
|
40–59
|
182 (22.3)
|
|
60–79
|
154 (18.8)
|
|
80–100
|
132 (16.1)
|
|
Not measured
|
53 (6.5)
|
|
Intended treatment at AML diagnosis
| |
|
Curative chemotherapy
|
501 (61.3)
|
|
Palliative chemotherapy
|
91 (11.1)
|
|
Best supportive care
|
218 (26.7)
|
|
Unknown
|
8 (1.0)
|
|
Vital status 1 y after the AML diagnosis date
|
|
Deceased
|
439 (53.7)
|
|
Alive
|
372 (45.5)
|
|
Unknownd
|
7 (0.9)
|
|
Vital status 2–5 y after the AML diagnosis date
|
|
Deceased
|
215 (57.8)e
|
|
Alive
|
96 (25.8)e
|
|
Unknownf
|
61 (17.5)e
|
